Medical device maker DexCom (NASDAQ: DXCM) has been trading in a fairly tight range recently, holding gains from the company's third-quarter report in late October. The stock is up 16.33% in the past ...

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. A warning letter posted Tuesday by the Food and Drug ...

DexCom’s patent involves a glucose monitoring system with a sensor that calculates in vivo sensitivity without needing a reference analyte measurement post-insertion. The system uses in vitro ...